Special Issue

10th Anniversary of *Biomedicines*—Intestinal Homeostasis and the Crosstalk within the Gut-Liver Axis

Message from the Guest Editors

The study of immune signals that stem at the intestinal level is an emerging field in immunology contributing to a better understanding of innate immune biology and the underlying events triggering immunometabolic effects within the gut-liver axis. In the context of biomedicine, intestinal homeostasis and the crosstalk within the gut-liver axis represent a path forward to selectively develop and maintain a long-lasting immune response(s). Intestinal immune interventions have been shown to be effective in hepatic metabolism regulation and immunity targeting tissue resident innate lymphoid cells and peripheral monocytes. Thus, harnessing intestinal immunometabolic homeostasis may benefit liver health and the control of related diseases. However, fundamental questions remain about immune and metabolic events that overall require a concerted effort to overcome the usually fragmented and compartmentalized approach to address the gut-liver axis. Identification and development of those, and the definition of their biomedical translation based on life sciences, can greatly accelerate our progress toward precision medicine in health promotion.

Guest Editors

Dr. Jose Laparra Llopis

Madrid Institute for Advanced Studies in Food (IMDEA Food), Madrid, Spain

Dr. Juan Antonio Giménez-Bastida

Laboratory of Food and Helath, Research Group on Quality, Safety and Bioactivity of Plant Foods, Department Food Science and Technology, CEBAS-CSIC, P.O. Box 164, Campus de Espinardo, 30100 Murcia, Spain

Deadline for manuscript submissions

closed (31 May 2023)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/106038

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).